Entrepreneurs: Newsmakers

Companies and a university are moving to offer cheaper and broader genetic testing for breast cancer risk to a growing group of women, following a U.S. Supreme Court ruling that ended Myriad Genetics Inc.’s monopoly over DNA that vastly raises odds for the disease.